{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-042895","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2023-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.694900+00:00","generated_at":"2026-06-11T08:17:48.544302+00:00","sec_items":["1.01","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Precision BioSciences sells azer-cel rights to Imugene for up to $227M; cash runway extended to Q3 2025","bullets":["Upfront consideration of $21M ($8M cash + $13M convertible notes); $8M milestone upon Phase 1b completion.","Eligible for up to $198M in additional milestones for azer-cel plus double-digit royalties on net sales.","Imugene gains global cancer rights to azer-cel and Precision's CAR T manufacturing infrastructure.","Precision expects to reduce annual operating spend by ~$20M, extending cash runway through Q3 2025.","Precision pivots exclusively to in vivo gene editing with ARCUS; retains non-oncology azer-cel rights."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-042895","json":"https://secwatch.observer/filing/0000950170-23-042895.json","markdown":"https://secwatch.observer/filing/0000950170-23-042895.md","text":"https://secwatch.observer/filing/0000950170-23-042895.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023042895/0000950170-23-042895-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023042895/dtil-20230815.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T08:17:48.544302+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ce72a9c549b4afb9d6c64fd217645d10846247bc","claim":"PRECISION BIOSCIENCES INC completed a disposition involving Imugene US for $8 million in cash and $13 million in convertible notes (closed 2023-08-15).","evidence_excerpt":"are associated with the Company’s CAR T cell therapy business. In consideration for the Acquired Assets, Imugene US assumed certain liabilities of the Company, paid the Company $8 million in cash, and issued to the Company convertible notes in an aggregate principal amount of $13 million. The convertible notes are non-interest bearing and mature on the first","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023042895/0000950170-23-042895-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Imugene US"},{"label":"Consideration","value":"$8 million in cash and $13 million in convertible notes"},{"label":"Closing","value":"2023-08-15"}],"fact_type":"ma_transaction"},{"claim_id":"0221e2a4921dbda7ffb841fa800e4224ef39d5c0","claim":"PRECISION BIOSCIENCES INC entered into License Agreement with Imugene (USA) Inc. valued at $206 million (effective 2023-08-15).","evidence_excerpt":"On the Closing Date, the Company and Imugene US entered into a License Agreement (the “License Agreement”), pursuant to which the Company granted Imugene US certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize oncological applications of the Company’s allogeneic CAR T therapy azer-cel and up to three additional research product candidates directed to targets that Imugene US may nominate prior to the fifth anniversary of the effective date of the License Agreement, pursuant to the terms of the License Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023042895/0000950170-23-042895-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Imugene (USA) Inc."},{"label":"Value","value":"$206 million"},{"label":"Effective","value":"2023-08-15"}],"fact_type":"material_agreement"},{"claim_id":"adfcd69dd29777e2bd994583467276f7d19ad90c","claim":"PRECISION BIOSCIENCES INC entered into Asset Purchase Agreement with Imugene Limited and Imugene (USA) Inc. (collectively, Imugene) valued at $8 million (effective 2023-08-15).","evidence_excerpt":"On August 15, 2023, Precision BioSciences, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Imugene Limited, an Australian corporation (“Imugene Limited”), and its wholly owned subsidiary Imugene (USA) Inc. (“Imugene US”), a Nevada corporation (collectively, “Imugene”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357874/000095017023042895/0000950170-23-042895-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Imugene Limited and Imugene (USA) Inc. (collectively, Imugene)"},{"label":"Value","value":"$8 million"},{"label":"Effective","value":"2023-08-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}